Should albumin be used in all patients with spontaneous bacterial peritonitis?

Can J Gastroenterol. 2011 Jul;25(7):373-6. doi: 10.1155/2011/586702.

Abstract

Patients with cirrhosis who develop spontaneous bacterial peritonitis (SBP) have been reported to experience a high incidence of renal impairment and mortality. Renal dysfunction is possibly related to altered systemic hemodynamics that leads to decreased effective arterial blood volume. Albumin, a plasma volume expander, has been investigated to determine whether it plays a role in patients with SBP. The current literature suggests that albumin can reduce renal impairment and mortality in high-risk SBP patients, defined as patients with a serum bilirubin level of greater than 68.4 μmol⁄L, a blood urea nitrogen level of greater than 10.7 mmol⁄L or a serum creatinine level greater than 88.4 μmol⁄L. The rationale for albumin and other volume expanders in SBP is discussed, accompanied by a review of the current literature.

Publication types

  • Review

MeSH terms

  • Albumins / administration & dosage
  • Albumins / pharmacology
  • Albumins / therapeutic use*
  • Bilirubin / blood
  • Humans
  • Kidney Diseases / etiology
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / drug therapy
  • Peritonitis / complications
  • Peritonitis / drug therapy*
  • Plasma Substitutes / administration & dosage
  • Plasma Substitutes / pharmacology
  • Plasma Substitutes / therapeutic use*
  • Renal Insufficiency / physiopathology

Substances

  • Albumins
  • Plasma Substitutes
  • Bilirubin